Sinopharm Revises Plan to Reform its State-Owned Enterprise Structure
July 21, 2016 at 04:44 AM EDT
Sinopharm, China's largest state-owned pharma, has submitted a plan to China's Assets Supervision and Administration Commission that would strengthen the power of its Board of Directors. Two years ago, Sinopharm was chosen as a pilot program for reform of China's state-owned enterprises as a way to make the SOEs more competitive, a mixed-ownership plan. A more powerful Board would implement market-based strategies for Sinopharm, reducing the power of the government to make decisions for China's largest pharma. Sinopharm is formally known as China National Pharmaceutical Group. More details.... Share this with colleagues: // //